300181 佐力药业
已收盘 01-09 15:00:00
资讯
新帖
简况
股市必读:佐力药业(300181)1月9日董秘有最新回复
证券之星 · 01:10
股市必读:佐力药业(300181)1月9日董秘有最新回复
佐力药业:后续如有回购注销计划将及时披露
证券之星 · 01-07
佐力药业:后续如有回购注销计划将及时披露
佐力药业:未来医药资产组收购事项正积极推进中
证券之星 · 01-06
佐力药业:未来医药资产组收购事项正积极推进中
每周股票复盘:佐力药业(300181)6145.8715万元竞得工业用地
证券之星 · 01-03
每周股票复盘:佐力药业(300181)6145.8715万元竞得工业用地
佐力药业,被700亿华东医药“追堵”
蓝鲸财经 · 2025-12-31
佐力药业,被700亿华东医药“追堵”
佐力药业:公司中药饮片业务主要是以杭州、湖州为中心深耕省内市场
证券日报 · 2025-12-24
佐力药业:公司中药饮片业务主要是以杭州、湖州为中心深耕省内市场
佐力药业:12月23日接受机构调研,华泰资产、东吴证券参与
证券之星 · 2025-12-24
佐力药业:12月23日接受机构调研,华泰资产、东吴证券参与
佐力药业(300181)披露拟向不特定对象发行可转换公司债券相关议案,12月19日股价上涨0.41%
证券之星 · 2025-12-19
佐力药业(300181)披露拟向不特定对象发行可转换公司债券相关议案,12月19日股价上涨0.41%
佐力药业:百令系列明年有望通过以价换量实现销售额持续增长
证券之星 · 2025-12-18
佐力药业:百令系列明年有望通过以价换量实现销售额持续增长
21股获推荐,泽璟制药、佐力药业目标价涨幅超30%
21世纪经济报道 · 2025-12-16
21股获推荐,泽璟制药、佐力药业目标价涨幅超30%
佐力药业最新公告:拟3.56亿元收购未来医药多种微量元素注射液资产组
证券之星 · 2025-12-14
佐力药业最新公告:拟3.56亿元收购未来医药多种微量元素注射液资产组
佐力药业最新公告:拟募资不超过15.56亿元用于智能化中药大健康工厂等
证券之星 · 2025-12-02
佐力药业最新公告:拟募资不超过15.56亿元用于智能化中药大健康工厂等
浙江佐力药业计划通过发行债券筹集最高16亿元用于项目和资本提升
美股速递 · 2025-12-02
浙江佐力药业计划通过发行债券筹集最高16亿元用于项目和资本提升
股市必读:佐力药业(300181)11月7日董秘有最新回复
证券之星 · 2025-11-10
股市必读:佐力药业(300181)11月7日董秘有最新回复
佐力药业:规模效应显现持续推动节支增效
证券之星 · 2025-11-07
佐力药业:规模效应显现持续推动节支增效
股市必读:佐力药业(300181)10月31日披露最新机构调研信息
证券之星 · 2025-11-03
股市必读:佐力药业(300181)10月31日披露最新机构调研信息
佐力药业:10月30日接受机构调研,中信证券、光大证券等多家机构参与
证券之星 · 2025-10-31
佐力药业:10月30日接受机构调研,中信证券、光大证券等多家机构参与
佐力药业(300181)9月30日股东户数4.14万户,较上期增加7.31%
证券之星 · 2025-10-28
佐力药业(300181)9月30日股东户数4.14万户,较上期增加7.31%
图解佐力药业三季报:第三季度单季净利润同比增长8.81%
证券之星 · 2025-10-27
图解佐力药业三季报:第三季度单季净利润同比增长8.81%
股市必读:佐力药业(300181)10月17日董秘有最新回复
证券之星 · 2025-10-20
股市必读:佐力药业(300181)10月17日董秘有最新回复
加载更多
公司概况
公司名称:
浙江佐力药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-02-22
主营业务:
浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵系列(乌灵胶囊、灵泽片、灵莲花颗粒)、百令系列(百令片、百令胶囊)、中药饮片及中药配方颗粒、聚卡波非钙片。2025年7月,由北京市经济和信息化局等单位联合主办、中国医药工业信息中心承办的2025第42届全国医药工业信息年会,公司荣膺2025年中国医药工业企业社会责任优秀案例榜单。
发行价格:
23.50
{"stockData":{"symbol":"300181","market":"SZ","secType":"STK","nameCN":"佐力药业","latestPrice":16.6,"timestamp":1767942195000,"preClose":16.46,"halted":0,"volume":13167440,"delay":0,"changeRate":0.0085,"floatShares":603000000,"shares":701000000,"eps":0.8502,"marketStatus":"已收盘","change":0.14,"latestTime":"01-09 15:00:00","open":16.52,"high":16.64,"low":16.35,"amount":217000000,"amplitude":0.0176,"askPrice":16.61,"askSize":297,"bidPrice":16.6,"bidSize":188,"shortable":0,"etf":0,"ttmEps":0.8502,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.46,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":18.11,"lowLimit":14.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":701387335,"isCdr":false,"pbRate":3.7,"roa":"--","peRate":19.524818,"roe":"18.05%","epsLYR":0.73,"committee":-0.62683,"marketValue":11643000000,"turnoverRate":0.0218,"status":0,"floatMarketCap":10008000000},"requestUrl":"/m/hq/s/300181","defaultTab":"news","newsList":[{"id":"2602552348","title":"股市必读:佐力药业(300181)1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602552348","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602552348?lang=zh_cn&edition=full","pubTime":"2026-01-12 01:10","pubTimestamp":1768151421,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,佐力药业报收于16.6元,上涨0.85%,换手率2.18%,成交量13.17万手,成交额2.17亿元。董秘最新回复投资者: 未来社会是智能化的社会,脑机智能将会占据重要地位,请问贵司对这个方向有哪些战略规划和储备,谢谢!股价波动受宏观环境及市场情绪等多重因素综合影响,公司将持续做好经营,努力提升经营效益,切实维护好广大投资者权益和资本市场稳定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200000489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300181","BK0042","BK0077"],"gpt_icon":0},{"id":"2601803848","title":"佐力药业:后续如有回购注销计划将及时披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601803848?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:51","pubTimestamp":1767790270,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问:公司股价逆大盘走势,持续性下跌,请问公司有没有回购注销计划,来稳定投资者信心。佐力药业回复:您好!公司将继续围绕发展目标经营管理好公司,努力提升经营效益,切实维护好广大投资者权益和资本市场稳定。后续如有回购注销相关计划,将严格按照有关法律法规的规定及时履行信息披露义务。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700036826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0042","300181"],"gpt_icon":0},{"id":"2601186265","title":"佐力药业:未来医药资产组收购事项正积极推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186265","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186265?lang=zh_cn&edition=full","pubTime":"2026-01-06 15:54","pubTimestamp":1767686054,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业01月06日在投资者关系平台上答复投资者关心的问题。请公司正面回应,大部分上市对股东人数回应都是很正常公开的。关于未来医药资产组收购事项,目前商业公司及代理商交接、技术资料对接等相关工作正在积极推进中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600021001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK1161","300181","BK0042","BK1574","09939","BK1515","159938"],"gpt_icon":0},{"id":"2600626900","title":"每周股票复盘:佐力药业(300181)6145.8715万元竞得工业用地","url":"https://stock-news.laohu8.com/highlight/detail?id=2600626900","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600626900?lang=zh_cn&edition=full","pubTime":"2026-01-03 01:55","pubTimestamp":1767376513,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,佐力药业报收于16.16元,较上周的16.77元下跌3.64%。本周,佐力药业12月29日盘中最高价报16.75元。佐力药业当前最新总市值113.34亿元,在中药板块市值排名19/67,在两市A股市值排名1719/5181。本周关注点公司公告汇总:佐力药业以6,145.8715万元成功竞得126,719平方米工业用地。公司公告汇总浙江佐力药业股份有限公司于2025年12月2日召开董事会,审议通过参与竞拍土地使用权的议案,同意使用自有资金不超过6,500万元竞拍工业用地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","300181","BK0077"],"gpt_icon":0},{"id":"2595716668","title":"佐力药业,被700亿华东医药“追堵”","url":"https://stock-news.laohu8.com/highlight/detail?id=2595716668","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595716668?lang=zh_cn&edition=full","pubTime":"2025-12-31 00:24","pubTimestamp":1767111866,"startTime":"0","endTime":"0","summary":"文|《投资者网》蔡俊最近,佐力药业不平静。外部,华东医药与公司的诉讼暂告段落,但还未迎来终局。其实,华东医药起诉的核心是与公司争夺百令系列产品。截至目前,公司、华东医药的市值分别约120亿元、700亿元。留“后手”+再造新曲线几乎在收购未来生物的同期,佐力药业与华东医药发布纠纷进展。根据公告,法院驳回华东医药子公司的全部诉讼请求,并要求其负担案件受理费。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766906460012125486","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","000963","BK0187","LU2328871848.SGD","BK0077","BK0132","BK0196","BK0209","BK0188","LU1969619763.USD","300181","BK0183","BK0175","BK0042"],"gpt_icon":0},{"id":"2593947410","title":"佐力药业:公司中药饮片业务主要是以杭州、湖州为中心深耕省内市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2593947410","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593947410?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:38","pubTimestamp":1766576280,"startTime":"0","endTime":"0","summary":"证券日报网12月24日讯 ,佐力药业在接受投资者提问时表示,公司中药饮片业务主要是以杭州、湖州为中心深耕省内市场,经过多年深耕,已在省内建立起品牌影响力,医院覆盖持续增加,业务整体保持稳定。中药配方颗粒方面,此前山东省牵头的集采,虽整体降幅较大,在价格层面形成一定引导,但公司业务主要还是省内为主,受集采直接影响有限。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxcti4389318.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-24/doc-inhcxcti4389318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0077","300181","BK0042"],"gpt_icon":0},{"id":"2593479163","title":"佐力药业:12月23日接受机构调研,华泰资产、东吴证券参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2593479163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593479163?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:01","pubTimestamp":1766574112,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年12月24日佐力药业发布公告称公司于2025年12月23日接受机构调研,华泰资产黄俊岭 张珈玮 曹耀元 王金成、东吴证券朱国广 向潇参与。佐力药业主营业务:药品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400031629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","BK0009","601555","BK0183","BK0239","BK0042","BK0028","BK0077","300181","BK0012","BK0188"],"gpt_icon":0},{"id":"2592198151","title":"佐力药业(300181)披露拟向不特定对象发行可转换公司债券相关议案,12月19日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592198151","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592198151?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:38","pubTimestamp":1766155084,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘,佐力药业报收于16.94元,较前一交易日上涨0.41%,最新总市值为118.82亿元。该股当日开盘16.86元,最高17.15元,最低16.85元,成交额达1.46亿元,换手率为1.42%。根据公司近日发布的公告,浙江佐力药业股份有限公司于2025年12月19日召开2025年第二次临时股东会,审议通过了关于公司符合向不特定对象发行可转换公司债券条件的议案、发行方案及相关预案、论证分析报告、募集资金使用可行性报告等事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","300181","BK0077"],"gpt_icon":0},{"id":"2592976986","title":"佐力药业:百令系列明年有望通过以价换量实现销售额持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2592976986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592976986?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:42","pubTimestamp":1766047333,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,公司和华东的官司已经胜诉,预计公司百令系列明年销量怎么样?佐力药业回复:您好!随着全国中成药采购联盟集采全面落地执行,百令系列明年有望通过以价换量的方式,实现销售额的持续增长,未来公司力争把百令系列打造成10亿规模的大品种。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800023281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","300181","BK0077"],"gpt_icon":0},{"id":"2591767248","title":"21股获推荐,泽璟制药、佐力药业目标价涨幅超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591767248","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591767248?lang=zh_cn&edition=full","pubTime":"2025-12-16 10:07","pubTimestamp":1765850820,"startTime":"0","endTime":"0","summary":"南财投研通数据显示,12月15日,券商给予上市公司目标价共6次,按最新收盘价计算,目标价涨幅排名居前的公司有泽璟制药、佐力药业、创世纪,目标价涨幅分别为35.00%、34.58%、27.40%,分别属于化学制药、中药、自动化设备行业。从券商推荐家数来看,12月15日有21家上市公司得到券商推荐,其中佐力药业获得5家推荐,天地科技、常宝股份等均获得1家推荐。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-16/doc-inhayftm3311202.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-16/doc-inhayftm3311202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300181","688266"],"gpt_icon":0},{"id":"2591650105","title":"佐力药业最新公告:拟3.56亿元收购未来医药多种微量元素注射液资产组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650105","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650105?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:39","pubTimestamp":1765701597,"startTime":"0","endTime":"0","summary":"佐力药业公告称,公司于12月12日与西藏未来生物医药股份有限公司及其两家全资子公司许昌未来制药有限责任公司和合肥市未来药物开发有限公司签署了《多种微量元素注射液资产组收购协议书》,拟以总价(含税)3.56亿元收购其多种微量元素注射液资产组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400003927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0239","09939","BK1161","BK0042","BK1574","BK0077","159938","BK1515"],"gpt_icon":0},{"id":"2588684034","title":"佐力药业最新公告:拟募资不超过15.56亿元用于智能化中药大健康工厂等","url":"https://stock-news.laohu8.com/highlight/detail?id=2588684034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588684034?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:31","pubTimestamp":1764671495,"startTime":"0","endTime":"0","summary":"佐力药业(300181.SZ)公告称,公司计划向不特定对象发行可转换公司债券募集资金总额不超过15.56亿元,扣除发行费用后的募集资金净额拟用于智能化中药大健康工厂(一期)、“乌灵+X”产品研发项目及补充流动资金。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200029232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0042","BK0077","BK0239"],"gpt_icon":0},{"id":"1123813301","title":"浙江佐力药业计划通过发行债券筹集最高16亿元用于项目和资本提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1123813301","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123813301?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:25","pubTimestamp":1764671115,"startTime":"0","endTime":"0","summary":"浙江佐力药业计划通过发行债券筹集最高16亿元,以支持项目发展和增强资本实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK0239","BK0042","300181"],"gpt_icon":0},{"id":"2582890177","title":"股市必读:佐力药业(300181)11月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582890177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582890177?lang=zh_cn&edition=full","pubTime":"2025-11-10 01:10","pubTimestamp":1762708222,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,佐力药业报收于17.53元,上涨0.86%,换手率1.74%,成交量10.47万手,成交额1.84亿元。乌灵胶囊目前还有6个省份未进入集采,公司将持续关注这些地区的动态,具体以相关省份发布的集采信息为准。投资者: 请问截止至2025年10月31日收盘公司股东人数为多少,谢谢董秘: 您好!公司高度重视应收账款管理,未来将持续加强应收账款的管理,严格执行信用管理制度,提高资金周转,保障公司健康稳定发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000000452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0042","300181","BK0239"],"gpt_icon":0},{"id":"2581074188","title":"佐力药业:规模效应显现持续推动节支增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2581074188","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581074188?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:00","pubTimestamp":1762502445,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业11月07日在投资者关系平台上答复投资者关心的问题。投资者提问:公司2020-2023年营业利润增速持续高于营收增速,反映出出色的成本控制能力。近几年来公司乌灵系列等产品的销售不断提升,规模效应得以体现,同时公司主要产品在集采地区价格下降,公司在生产端和销售端协同降低相关合理的费用。随着业务规模扩大,公司将持续推进精益管理、创新引领等一系列措施,以实现可持续的高质量发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700023219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300181","BK0042","BK0239"],"gpt_icon":0},{"id":"2580331042","title":"股市必读:佐力药业(300181)10月31日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2580331042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580331042?lang=zh_cn&edition=full","pubTime":"2025-11-03 03:08","pubTimestamp":1762110493,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,佐力药业报收于17.53元,上涨2.34%,换手率2.21%,成交量13.33万手,成交额2.33亿元。来自机构调研要点:三季度毛利率下滑主因产品结构变化及集采降价影响,应收账款增长与收入上升和医保结算周期相关。截至三季度末,乌灵胶囊已经覆盖 15000 多家医院。百令系列参与的全国中成药联盟集采已有30个省份发布集采执行通知,进入全面铺开阶段。截至目前,百令片覆盖医院约4000家;百令胶囊为新进品种,正在加速开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300000667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0077","300181","BK0239"],"gpt_icon":0},{"id":"2579677554","title":"佐力药业:10月30日接受机构调研,中信证券、光大证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2579677554","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579677554?lang=zh_cn&edition=full","pubTime":"2025-10-31 21:31","pubTimestamp":1761917508,"startTime":"0","endTime":"0","summary":"答:截至三季度末,乌灵胶囊已经覆盖 15000 多家医院。截至目前,百令片覆盖医院约 4000 家;百令胶囊为新进入品种,正在加快开发。佐力药业主营业务:药品的研发、生产和销售。佐力药业2025年三季报显示,前三季度公司主营收入22.8亿元,同比上升11.48%;归母净利润5.1亿元,同比上升21.0%;扣非净利润5.09亿元,同比上升22.51%;其中2025年第三季度,公司单季度主营收入6.8亿元,同比上升10.32%;单季度归母净利","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100048440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601788","LU0405327148.USD","LU1064131003.USD","LU1655091616.SGD","BK1521","06030","BK0077","BK1564","BK0196","LU2495084118.USD","LU1997244956.HKD","BK0012","300181","BK0276","LU1794554557.SGD","BK1147","BK1516","BK0183","BK0239","LU1720050803.USD","600030","LU2148510915.USD","LU0405327494.USD","LU1997245094.SGD","LU1997245177.USD","LU1328615791.USD","LU1255011170.USD","LU2289578879.USD","BK0028","BK0042","LU1064130708.USD","BK0188","06178"],"gpt_icon":0},{"id":"2578939187","title":"佐力药业(300181)9月30日股东户数4.14万户,较上期增加7.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578939187","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578939187?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:38","pubTimestamp":1761644319,"startTime":"0","endTime":"0","summary":"证券之星消息,近日佐力药业披露,截至2025年9月30日公司股东户数为4.14万户,较6月30日增加2822.0户,增幅为7.31%。在中药行业个股中,佐力药业股东户数低于行业平均水平,截至9月30日,中药行业平均股东户数为5.36万户。从股价来看,2025年6月30日至2025年9月30日,佐力药业区间涨幅为2.71%,在此期间股东户数增加2822.0户,增幅为7.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800032116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300181","BK0042","BK0239"],"gpt_icon":0},{"id":"2578447610","title":"图解佐力药业三季报:第三季度单季净利润同比增长8.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578447610","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578447610?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:09","pubTimestamp":1761563399,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业2025年三季报显示,公司主营收入22.8亿元,同比上升11.48%;归母净利润5.1亿元,同比上升21.0%;扣非净利润5.09亿元,同比上升22.51%;其中2025年第三季度,公司单季度主营收入6.8亿元,同比上升10.32%;单季度归母净利润1.36亿元,同比上升8.81%;单季度扣非净利润1.37亿元,同比上升11.28%;负债率31.46%,投资收益-218.41万元,财务费用660.37万元,毛利率62.03%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700029521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"gpt_icon":0},{"id":"2576575077","title":"股市必读:佐力药业(300181)10月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2576575077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576575077?lang=zh_cn&edition=full","pubTime":"2025-10-20 00:55","pubTimestamp":1760892912,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘,佐力药业报收于18.65元,下跌2.46%,换手率2.89%,成交量17.41万手,成交额3.29亿元。董秘最新回复投资者: 请问截止9月30日公司股东人数是多少?公司根据法律法规要求履行信息披露义务,将于10月28日披露2025年三季度报告。当日关注点来自交易信息汇总:10月17日主力资金净流出5931.12万元,散户资金净流入5899.53万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000000419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300181","BK0042","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768156311081,"stockEarnings":[{"period":"1week","weight":0.0272},{"period":"1month","weight":-0.0621},{"period":"3month","weight":-0.0874},{"period":"6month","weight":-0.1194},{"period":"1year","weight":0.198},{"period":"ytd","weight":0.0272}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江佐力药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41403人(较上一季度增加7.31%)","perCapita":"14562股","listingDate":"2011-02-22","address":"浙江省湖州市德清县阜溪街道志远北路388号","registeredCapital":"70138万元","survey":" 浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵系列(乌灵胶囊、灵泽片、灵莲花颗粒)、百令系列(百令片、百令胶囊)、中药饮片及中药配方颗粒、聚卡波非钙片。2025年7月,由北京市经济和信息化局等单位联合主办、中国医药工业信息中心承办的2025第42届全国医药工业信息年会,公司荣膺2025年中国医药工业企业社会责任优秀案例榜单。","listedPrice":23.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佐力药业,300181,佐力药业股票,佐力药业股票老虎,佐力药业股票老虎国际,佐力药业行情,佐力药业股票行情,佐力药业股价,佐力药业股市,佐力药业股票价格,佐力药业股票交易,佐力药业股票购买,佐力药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}